WO1990012870A1 - Monoclonal antibody to amyloid peptide - Google Patents

Monoclonal antibody to amyloid peptide Download PDF

Info

Publication number
WO1990012870A1
WO1990012870A1 PCT/US1990/002002 US9002002W WO9012870A1 WO 1990012870 A1 WO1990012870 A1 WO 1990012870A1 US 9002002 W US9002002 W US 9002002W WO 9012870 A1 WO9012870 A1 WO 9012870A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
monoclonal antibody
antibody
alzheimer
individuals
cells
Prior art date
Application number
PCT/US1990/002002
Other languages
French (fr)
Inventor
Kwang S. Kim
Henryk M. Wisniewski
David L. Miller
Cheng-Mo James Chen
Victor J. Sapienza
Inge Grundke Eqbal
Original Assignee
Research Foundation For Mental Hygiene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein

Abstract

Disclosed is a monoclonal antibody and specific-binding fragment thereof which is specifically reactive with a peptide whose concentration level is elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted and which monoclonal antibody and specific-binding fragment thereof does not react with other peptides of human origin. Also disclosed is a hybridoma cell line capable of producing the monoclonal antibody, a reagent composition which incorporates the monoclonal antibody or specific-binding fragments thereof and an immunoassay method for their use.

Description

ϋ MONOCLONAL ANTIBODY TO AMYLOID PEPTIDE

BACKGROUND OF THE INVENTION

Field Of The Invention 5 The present invention relates to neurological disorders, and, more particularly, to monoclonal antibodies that are specific for peptides associated therewith.

0 Brief Description Of The Prior Art

Alzheimer's disease is characterized by three major pathological markers. They are neuritic plaques, neurofibrillary tangles and cerebrovascular amyloidosis. Glenner, et al., Biochem. Biophys. Res. 5 Comm. , 120:885 (1984) and Wisniewski, et al., Int. Symp. Dementia and Amyloid "Neuropathology" , Suppl. .3:87 (1986). Alzheimer's cerebrovascular amyloid protein has been purified and a 24 amino acid residue sequence has been reported. Glenner, et al., 0 Biochem. Biophys. Res. Comm., 122:1131 (1984). It has also been observed that the sequenced portion of the cerebrovascular amyloid peptide is part of the sequence of a precursor protein. Robakis, et al., Proc. Nat. Acad. Sci. USA, £4:4190 (1987) and 5 Robakis, et al., The Lancet, 1:384 (1987).

Down's Syndrome is a disability characterized by the inheritance of an extra copy of chromosome 21 in each cell. Older persons afflicted with Down's Syndrome display dementia that resembles 0 Alzheimer's disease. The cerebral tissues of these individuals exhibit the same neuropathological findings of Alzheimer's disease, i.e., amyloid-containing neuritic plaques, neurofibrillary tangles and cerebrovascular amyloidosis. The amyloid 5 deposits of Down's Syndrome contain the same peptide as the amyloid deposits found in the brains of

Alzheimer's disease victims. See, Glenner et al., Biochem. Biophys. Res. Comm., 122:1131 (1984).

As applied to other peptides and antigens, including many associated with various diseases, monoclonal antibody products of hybridoma technology have often proven valuable in studying factors associated with these diseases and in diagnosis of the disease in clinical settings. Kim, et al., Neuroscience Research Communications, 2:121 (1988) discloses production and characterization of monoclonal antibodies specific for the synthetic cerebrovascular amyloid protein described in Glenner et al., Biochem. Biophys. Res. Comm., 122:1131 (1984), supra.

SUMMARY OF THE INVENTION Hybridoma technology is one of the most important biological tools for the analysis of complex antigens. Using the monoclonal antibodies of the present invention, which are specific to recently acquired amino acid sequences of beta - amyloid precursor proteins, it has become possible to study the beta-amyloid precursor protein which leads to significant deposits of vascular and neuritic amyloid plaques in Alzheimer's disease and Down's syndrome.

These monoclonal antibodies provide the potential for non-invasive diagnosis thereof using body fluids such as spinal fluid, serum or urine.

In one aspect, the invention provides a monoclonal antibody and antigen - binding fragment thereof which are specifically reactive with a peptide whose concentration level is elevated in individuals having Alzheimer's disease or Down's syndrome as compared to individuals of substantially the same age who are not so-afflicted and which do not react with other peptides of human origin. The monoclonal antibodies of the invention are primarily of subclass IgG, , while others are of a subclass selected from IgG_ , IgG2b and IgM. Papain - digestion produced antigen - binding fragments (e.g. Fab) have also been shown to specifically recognize amyloid plaque.

The monoclonal antibody is produced by a hybridoma formed by fusion of cells from a myeloma line, usually of mouse origin, and antibody-producing cells, also usually of mouse origin, previously immunized with a peptide whose concentration level is elevated in individuals having Alzheimer's disease or Down's syndrome as compared to individuals of substantially the same age who are not so-afflicted and which do not react with other peptides of human origin, such as one which forms a portion of a cerebrovascular amyloid plaque characteristic of Alzheimer's disease or Down's syndrome. Preferably, a mouse NSO myeloma line is used, particularly with antibody-producing cells from a mouse previously immunized with a peptide having a C-terminal sequence comprising leu - val - phe - phe - ala - glu - asp - val. Examples are monoclonal antibody SCVAP-2F9 and monoclonal antibody SCVAP-4G8. Further in this regard, the invention provides a hybridoma cell line capable of producing the monoclonal antibodies described above.

In another aspect, the invention provides a composition for quantitatively determining a peptide whose concentration level is characteristic of Alzheimer's disease or Down's syndrome in an individual. The composition comprises a monoclonal antibody or antigen - binding fragment thereof in accordance with the invention and a detectable moiety which is directly or indirectly associated therewith. In one embodiment, the monoclonal antibody is conjugated to an enzyme and the detectable moiety comprises a chromogenic redox substrate for the enzyme. In another embodiment, the monoclonal antibody is conjugated to one partner of a specific binding pair and the other partner of the specific binding pair is conjugated to a detectable moiety or a substance capable of rendering the moiety detectable. One example of this embodiment is where the monoclonal antibody or antigen - binding fragment thereof additionally serves as an antigen of the specific binding pair. The partner for the monoclonal or fragment is an anti-immunoglobulin antibody, usually anti - IgG and usually from a species other than that of its partner, which is labeled, such as with a fluorophore like fluorescein isothiocyanate. Another example is where one partner of the specific binding pair is selected from biotin and its binding analogs and the other partner is selected from avidin and its binding analogs. Usually, the detectable moiety is a chromophore, fluorophore or luminophore and the substance capable of rendering it detectable is an energy donor or catalyst therefor. * Further in this regard, the invention provides an immunoassay method. The method comprises contacting a sample, from the individual suspected of having Alzheimer's disease or Down's syndrome, with the composition of the invention and quantitatively observing any detectable response.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph illustrating that the relative OD reading between concentrations of SCVAP in the range shown can be quantitated using the method in accordance with the invention. The ϋ sensitivity of the method is in the range of 0.2 to 0.4 ng/100 ul of SCVAP in solution.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

5 Example 1

Monoclonal Antibody (mAB) To Synthetic Cerebrovascular Amyloid Peptide (SCVAP) and Fragments In the experiments reported by this example, 0 a synthetic polypeptide, an antigenic conjugate thereof and tryptic fragments of the polypeptide were used to prepare and characterize the monoclonal antibodies of the invention.

5 Preparation of SCVAP and Fragments

Preparation of SCVAP and its tryptic fragments was as follows. A 24-residue synthetic cerebrovascular amyloid peptide (SCVAP) corresponding to the published sequence of the Alzheimer's 0 cerebrovascular amyloid peptide was obtained from Peninsula Laboratories, Belmont, CA. The sequence mentioned was published in Glenner, et al., Biochem. Biophys. Res. Comm., 120:885 (1984). The preparation as received was purified by reverse phase liquid 5 chromatography and the sequence was confirmed by amino-terminal sequencing as described in Bobin, et al., Acta Neuropathol. , 4-.313 (1987). The purified peptide (1 mg) was conjugated to keyhole-limpet hemocyanin (6 mg) with glutaraldehyde (3 ul) in 0 sodium phosphate (1.2 ml, 50 mM, pH 7.5) at 4°C for 2 hours to provide the SCVAP-KLH antigen.

The purified peptide was also cleaved using trypsin into fragments containing residues 1-5, 6-16, 6-24 and 17-24 as follows. The peptide (1 mg) in 0.1 5 M H4HC03 (500 ul) was treated with TPCK-treated trypsin (Cooper Biomedical, Malvern, PA) overnight at 37°C. The peptide fragments were resolved by reverse-phase chromatography on a 4.6 x 50 mm C-8 column (J.T. Baker, Phillipsburg, NJ) eluted with a linear gradient of 0-60% acetonitrile in 0.1% trifluoroacetic acid for 40 minutes at 1 ml/minute. The fragments were identified by amino analysis and the sequences were determined to be as follows:

Fragment Residues Sequence 1 1-5 DAEFR

2 6-16 HDSGYQVHHQK

3 6-24 HDSGYQVHHQKLVFFAEDV

4 17-24 LVFFAEDV

Amino acids are designated by one-letter symbols in accordance with the convention described, inter alia, in Lehninger, Biochemistry (2nd Ed.) . Worth Publishers, Inc., New York, pg. 72 (1975). These fragments were used, as described below, to sublocalize the epitopes of the monoclonal antibodies prepared as described herein.

Preparation of Hybrid Cell Lines

Procedures for producing antibody-secreting hybrid cell lines as described in Togashi, et al., Arch. Virol., £2:149 (1981) and modified as described in Kim, et al., J. Clin. Microbiol., 1S.:331 (1983) were applied as follows.

BALB/CJ female mice (Jackson Laboratories, Bar Harbor, ME) were immunized via the back foot pads with Ribi adjuvant (200 ul) (Ribi Immunochem

Research, Inc., Hamilton, MT) containing SCVAP-KLH antigen (25-50 ug) . At 21 days after the initial injection, these mice were immunized , intraperitoneally with SCVAP-KLH antigen (25-50 ug) in Ribi adjuvant (200 ul) . Four days prior to fusion, at 6 weeks after the last immunization, the mice received intraperitoneal booster injections of SCVAP (200 ug) without adjuvant. Immune spleen cells were harvested as described in Galfre, et al., Methods Enzymol., 3_:73 (1981). A mouse with the highest titer after SCVAP-KLH antigen immunization was selected for hybrid clone production.

NSO myeloma cells were obtained from Dr.

Choi, Kyung Hee of Albert Einstein Medical School,

New York, NY. The immune spleen cells were incubated with the NSO myeloma cells and fused at a ratio of

5:1 in the presence of polyethyleneglycol 1500

(Boehringer Mannheim, Indianapolis, IN) as the fusing agent. The cells were maintained in Iscoves modified

Dulbecco minimum essential medium containing 15%

4 fetal bovine serum, 10- M hypoxanthme, 1.6 x

10- 5 M thymidine and 4.0 x 10-7 M aminopteπn for

14 days. Subsequent feedings with medium containing only hypoxanthine and thymidine were performed on days 18, 22 and 25. After day 25, cells were fed with medium that did not include hypoxanthine, thymidine and aminopterin. Normal BALB/CJ mouse macrophages (6,000 cells per well in 96 wells of a microtiter plate) as a feeder layer were used for the initial hybridoma production.

Establishment of Hybrid Clones Secreting Anti-SCVAP mABs

After the initial hybridoma production, as 4 described above, 5 x 10 hybridoma cells in 1.0 ml were added to each well of 96 well tissue culture plates. After 2 to 4 weeks of incubation, hybrid cell growth was detected in 300 of 420 wells. The supernatant fluid in 122 of hybrids from the 300 wells were found to contain SCVAP-specific antibody as determined by ELISA, as described below. u Hybrids that produced SCVAP specific antibody, as determined by the ELISA procedure, were cloned three times by limiting dilutions to obtain pure clones. Normal BALB/CJ mouse macrophages (6,000 cells per well in 96 wells of a microtiter plate) as a feeder layer were used here also. Fifty (50) stable cloned hybrid cell lines were established and are referred to here as purified antibodies. From these, thirty (30) well-adapted, good antibody producers were grown in tissue culture flasks and further characterized.

ELISA Screening for Anti-SCVAP mABs

Hybridoma cells were tested for the production of SCVAP antibodies by the ELISA technique 5 as described by Kim et al., J. Clin. Microbiol.,

1£:331 (1983). SCVAP antigen was coated onto Falcon 96 well, 3911 Micro Test 111TM flexible assay plates by adding 50 ul of SCVAP antigen (1 ul/ l) in carbonate buffer (ph 9.6) and incubating overnight at 0 4°C. The substrate used was 3,3",5,5'- tetramethylbenzidine (TMB) (1 ml of 10% stock solution of TMB dissolved in dimethyl sulfoxide, 100 ml of 0.1 M sodium acetate/citric acid buffer, pH 6.0, 148 ul of 30% hydrogen peroxide). Substrate 5 solution was added to each well (100 ul/well) and incubated at room temperature for 30 minutes. The reaction was stopped by adding 2 M sulfuric acid (25 ul) to each well. The color change was measured with a Dynatech Micro Elisa Auto Reader MR580, using a 450 0 nm filter.

The antibody titers as determined by ELISA for tissue culture supernatant and ascites fluids were mostly around 1:20,000 and 1:1,000,000, respectively. 5 Characterization of Immunoglobulin Subclasses

Monoclonal antibodies produced as described above were recovered from culture fluids and characterized by Ouchterlony double diffusion tests with goat anti-mouse antibody specific to IgG, , IgG ' IgG 2b' IgG 3 an^ I9M- τlιe reagents were obtained from Meloy Laboratories, Inc., Springfield, VA. Most of the clones secreted the IgG, subclass of immunoglobulin; very few secreted IgG, . IqG2. and IgM subclasses and none secreted the IgG_ subclass.

Characterization of SCVAP mAB-Inducing Epitope

The SCVAP epitope for the monoclonal antibodies from the thirty (30) clones selected was determined as follows. To identify the amino acid sequence(s) in SCVAP which are immunogenic epitopes to monoclonal antibodies produced against SCVAP, SCVAP was trypsin digested as described above and fragments containing residues 1-5, 6-24, 6-16 and 17-24 were obtained. When each of the monoclonal antibodies were tested against these peptide fragments by ELISA, all of them reacted with peptides containing the amino acid sequences 1-24, 6-24 and 17-24 and none reacted with those containing the 6-16 or 1-5 amino acid residues.

These data demonstrate that amino acid residues 17-24 are those which form the antigenic domain that induced production of the anti-SCVAP antibodies described above. It was surprising to find that this sequence contained the preferred epitope. This region is composed of the sequence leu - val - phe - phe - ala - glu - asp - val, in which six of the eight residues are hydrophobic and are probably restricted in a beta-helix. According to the rules that good epitopes should be hydrophilic and mobile, one would not predict that this sequence would be especially antigenic. Because these antibodies react as strongly with purified cerebrovascular amyloid protein and amyloid core proteins as they do with SCVAP, it is concluded that this epitope is equally exposed in the natural amyloids and the synthetic peptide.

Example 2 Determination of Antigenic Determinant Commonality In the experiments reported by this example, monoclonal antibodies purified from mouse ascites fluid were used in immunoassays in competition with homologous and heterologous antibody preparations to determine if they had epitopic sequences in common.

Preparation of Purified mABs from Ascites Fluid

From the cloned hybrid cell lines, prepared as described in Example 1, that continued to produce antibody for 3 months, ascites fluid was obtained by mtraperitoneal infection of 10 7 cells into BALB/CJ mice which had been pretreated with 0.25 ml of pristane (2,6,10,14-tetramethyl-pentadecane) 1 and 8 days before injection.

Immunoglobulins of the IgG subclasses were purified from the ascites fluid with the Affi-Gel Protein A MAPS system (Bio-Rad Laboratories, Richmond, CA) . The purified IgG fractions from the Protein A MAPS column were combined and dialyzed against several changes of PBS and stored at -70°C until used. Monoclonal antibodies obtained in this manner are referred to herein as purified antibody. Anti-SCVAP AB - Horseradish Peroxidase (HRP) Conjugate

HRP was conjugated to anti-SCVAP monoclonal antibodies from each of the purified preparations by the periodate method described in Wilson and Nakane, In Knapp et al(eds.), Immunofluorescence and Related Techniques, Elsevier Sci. Publ. Co., Amsterdam, pp. 215-225 (1978). The conjugate solution was stored at 70°C in small aliquots after adding 1% BSA, 50% glycerol and 0.01% Thimerosal.

Identification of Antigenic Peterminants

For each monoclonal antibody a fixed amount of HRP-conjugated antibody (1:5,000 dilution of stock conjugate) was mixed with various amounts (1, 10, 100 ug/ml) of either unlabelled homologous or one of the other (heterologous) monoclonal antibodies and added to ELISA plate wells coated with limiting concentrations of SCVAP antigen.

All of the monoclonal antibodies reactive to residues 17-24 (Fragment 4) effectively competed with each other and, therefore, appear to be directed either against the same epitope, or overlapping epitopes present in the amino acid sequence of residues 17-24.

Example 3 Immunocytochemistrv of Alzheimer-Specific mABs

In this example, culture supernatants of 44 initial clones which exceeded 1.5 OD units in ELISA on SCVAP-coated wells were screened for im unocytochemical staining of cerebral amyloid.

Immunostaining Procedure

All supernatants were diluted with equal volumes of PBS containing 20 mg/ml BSA and applied on 6 urn sections of paraffin-embedded, formalin fixed Alzheimer cortex. Bound antibodies were visualized using the avidin biotin complex technique (ABC Kit, Vector Labs, Burlingame, CA) as described in Wang et al., Acta Neuropathol. (Berl. ) , £2:268 (1984). Selected supernatants were also tested on sections of Alzheimer hippocampus, a non-demented aged subject and tangles-containing neuronal cell bodies isolated from Alzheimer cortex as described in Iqbal et al., Acta Neuropathol. (Berl.) , .62:167 (1984). In some instances tissue sections were dephosphorylated prior to application of the antibodies using 43 ug/ml calf intestinal alkaline phosphatase type VII (Sigma B.ochemicals, St. Louis, MO). In this regard, see Grundke-Iqbal et al., Proc. Nat. Acad. Sci. USA, 12:4913 (1986) and Grundke-Iqbal et al., J. Biol. Che ., 12:6084 (1986).

Immunostaining of Cerebral Amyloid - Results Fifty (50) percent of the culture supernatants reactive with the 17-24 amino acid sequence of SCVAP also strongly reacted with amyloid present in neuritic plaques and cortical and meningeal vessels both in brain sections of Alzheimer patients and non-demented controls. No staining of Alzheimer neurofibrillary tangles or axons/neurofilaments either in tissue sections or in isolated neurons was observed with any of the supernatants.

In the case of the tangles, access of the monoclonal antibody tau-1 to microtubule associated polypeptides , tau-1 is known to be blocked by phosphorylation , as reported in Grundke-Iqbal, P.N.A.S. USA, s E-ta. Therefore, tissue sections were also treated with alkaline phosphatase before immunostaining with the anti-SCVAP antibodies. ° However, no change in immunostaining pattern or intensity was observed when the tissue sections or tangles containing neurons were dephosphorylated prior to application of immunocytochemically reactive or unreactive antibodies. 5

Example 4 Immunohistology Using Alzheimer-Specific mABs

In the experiments reported by this example, purified cerebrovascular amyloid peptides and 0 purified neuritic plaque amyloid core peptides were used for testing of recognition by monoclonal antibody specific for Fragment 4, described in Example 1.

5 Preparation of Cerebrovascular A yloid Peptides

Cerebrovascular amyloid material was obtained from autopsy-derived meninges as described by Glenner and Wong, Biochem. Biophys. Res. Commun., 120:885 (1984). Cerebrovascular amyloid peptides 0 were isolated by size exclusion chromatography and reverse-phase chromatography as follows. Cerebrovascular amyloid was dissolved in 6 M guanidine HC1-50 mM Tris HC1, pH 7.5. The solution was dialyzed and lyophilized, and the residue of 5 amyloid peptides was dissolved in 70% formic acid, 0.1% acetonitrile. This preparation was chromatographed on a 1 x 30 cm Pharmacia HR-12 size exclusion column equilibrated with the preceding solvent. The fractions containing cerebrovascular 0 amyloid peptide were dried and further fractionated on a J.T. Baker C-8 column 0.4 x 10 cm in a solvent containing 0-60% acetonitrile in 40% formic acid.

5 ° Preparation of Neuritic Plaque Core Peptides

Neuritic plaque amyloid cores were prepared as described by Bobin, et al., Acta. Neuropathol., 74:313 (1987). Briefly, autopsy material shown to be rich in neuritic plaque cores was homogenized in 5 phosphate-buffered saline (PBS), pH 7.0, and centrifuged through 10 M sucrose to remove lipids. The pellet was digested with pepsin and collagenase and sedimented through Percoll. The layer containing the amyloid cores was further washed with 6 M guanidine HC1, 8 M urea, and 10% sodium deoxycholate to remove adherent lipids and cerebrovascular amyloid, Neuritic plaque amyloid core peptides were purified by the same procedure as used for the purification of the cerebrovascular amyloid peptides, except that the cores were initially dissolved in 90% .formic acid.

Anti-SCVAP Fragment 4 mAB to Amyloid Core and Peptide Monoclonal antibodies specific for amyloid 0 residues (Fragment 4) selectively stained both plaque core amyloid and cerebrovascular amyloid in brain tissue from patients with histologically confirmed Alzheimer's disease. These monoclonal antibodies were further tested for their immunoreactivity by ELISA using 96 well plastic plates coated with the purified neuritic plague core amyloid peptides and cerebrovascular amyloid peptides prepared as described above. All of these monoclonal antibodies reacted well with peptides from both amyloid core and cerebrovascular plaque by ELISA.

Example 5 Quantitative Diagnostic Alzheimer ELISA Method A quantitative ELISA procedure for the 5 detection of SCVAP in solution using the monoclonal antibodies of the present invention was developed as follows.

Fifty (50) ul of various dilutions of monoclonal antibody SCVAP 4G8-HRP conjugate (a specific monoclonal antibody reactive to residues 17-24 of Alzheimer amyloid peptide conjugated to horseradish peroxidase) were titrated by ELISA on wells coated with the maximum amount of SCVAP antigen (5 ug/ml) .

The dilution of monoclonal antibody SCVAP 4G8-HRP conjugate that gave a relative OD reading close to 1.0 when incubated with TMB for 30 minutes as described above was determined. This concentration of monoclonal antibody SCVAP 4G8-HRP conjugate was mixed with an equal volume of SCVAP solution containing varying concentrations of SCVAP and incubated overnight at 4°C. The amount of unadsorbed monoclonal antibody SCVAP 4G8-HRP conjugate was then measured by titrating the mixture on ELISA 96 well plates coated with 5 ug/ml of SCVAP. After 4 hours of incubation at room temperature the ELISA OD was determined by using TMB as the substrate.

As shown in Fig. 1, the relative OD reading between concentrations of SCVAP in this range can be quantitated using this method. The sensitivity of the method is in the range of 0.2 to 0.4 ng/100 ul of SCVAP in solution.

Claims

WHAT IS CLAIMED IS:
1. A monoclonal antibody or antigen - binding fragment thereof which is specifically reactive with a peptide whose concentration level is elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted and which does not react with other peptides of human origin.
2. The monoclonal antibody or binding fragment of claim 1 which is specifically reactive with a cerebrovascular amyloid protein whose elevated levels are characteristic of Down's syndrome and Alzheimer's disease.
3. The monoclonal antibody or binding fragment of claim 1 which is of subclass IgG,. i
4. The monoclonal antibody or binding fragment of claim 1 which is of a subclass selected from the group consisting of IgG_ , IgG_, and IgM.
5. The monoclonal antibody or binding fragment of claim 1 which is produced by a hybridoma formed by fusion of cells from a mouse myeloma line and antibody-producing cells from a mouse previously immunized with a peptide whose concentration level is elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted and which does not react with other peptides of human origin.
6. The monoclonal antibody or binding fragment of claim 1 which is produced by a hybridoma formed by fusion of cells from a mouse myeloma line and ° antibody-producing cells from a mouse previously immunized with a cerebrovascular amyloid protein whose elevated levels are characteristic of Alzheimer's disease or Down's syndrome.
5 7. The monoclonal antibody or binding fragment of claim 1 which is produced by a hybridoma formed by fusion of cells from a mouse NSO myeloma line and antibody-producing cells from a mouse previously immunized with a peptide whose concentration level is 0 elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted.
8. The monoclonal antibody or binding fragment of 5 claim 1 which is produced by a hybridoma formed by fusion of cells from a mouse NSO myeloma line and antibody-producing cells from a mouse previously immunized with a cerebrovascular amyloid protein whose elevated levels are characteristic of 0 Alzheimer's disease or Down's syndrome.
9. A monoclonal antibody which is produced by a hybridoma formed by fusion of cells from a mouse NSO myeloma line and antibody-producing cells from a 5 mouse previously immunized with a peptide having a
C-terminal sequence comprising leu - val - phe - phe - ala - glu - asp - val, or an antigen - binding fragment of said monoclonal antibody.
0 10. A monoclonal antibody selected from the group consisting of monoclonal antibody SCVAP 2F9 and monoclonal antibody SCVAP 4G8, or an antigen - binding fragment of said monoclonal antibody.
5
11. A hybridoma cell line capable of producing the monoclonal antibody of claim 1.
12. The hybridoma cell line of claim 11 which is formed by fusion of cells from a myeloma line and antibody-producing cells previously immunized with a peptide whose concentration level is elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted.
13. The hybridoma cell line of claim 11 which is formed by fusion of cells from a mouse myeloma line and antibody-producing cells from a mouse previously immunized with a peptide whose concentration level is elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted.
14. The hybridoma cell line of claim 11 which is formed by fusion of cells from a mouse NSO myeloma line and antibody-producing cells from a mouse previously immunized with a peptide whose concentration level is elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted.
15. The hybridoma cell line of claim 11 which is formed by fusion of cells from a mouse NSO myeloma line and antibody-producing cells from a mouse previously immunized with a peptide having a C-terminal sequence comprising leu - val - phe - phe - ala - glu - asp - val. ° 16. A composition for quantitatively determining a peptide whose elevated levels are characteristic of Alzheimer's disease or Down's syndrome in an individual, which composition comprises the monoclonal antibody or specific - binding fragment of
5 claim 1 and a detectable moiety which is directly or indirectly associated therewith.
17. The composition of claim 16 wherein said monoclonal antibody or specific - binding fragment is 0 conjugated to an enzyme and said detectable moiety comprises a chromogenic redox substrate for said enzyme.
18. The composition of claim 16 wherein said 5 monoclonal antibody or specific - binding fragment is specifically bindable with a substance attached to said detectable moiety.
19. The composition of claim 18 wherein the substance 0 attached to said detectable moiety is an antibody specifically bindable with an immunoglobulin.
20. The composition of claim 16 wherein said monoclonal antibody is conjugated to one partner of a 5 specific binding pair and which further comprises the other partner of said specific binding pair conjugated to said detectable moiety or a substance capable of rendering said moiety detectable.
0 21. The composition of claim 20 wherein one partner of said specific binding pair is selected from the group of biotin and its binding analogs and the other partner of said binding pair is selected from the group of avidin and its binding analogs. 5
° 22. The composition of either of claims 20 or 21 wherein said detectable moiety is a chrornophore, fluorophore or luminophore and said substance capable of rendering said moiety detectable is an energy donor or catalyst therefor. 5
23. A method for quantitatively determining a peptide whose elevated levels are characteristic of Alzheimer's disease or Down's syndrome in an individual, which method comprises contacting a 0 sample from said individual with the composition of any of claims 16-20 and quantitatively observing any detectable response.
5
0
5
0
5
PCT/US1990/002002 1989-04-14 1990-04-13 Monoclonal antibody to amyloid peptide WO1990012870A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US33830289 true 1989-04-14 1989-04-14
US338,302 1989-04-14

Publications (1)

Publication Number Publication Date
WO1990012870A1 true true WO1990012870A1 (en) 1990-11-01

Family

ID=23324245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/002002 WO1990012870A1 (en) 1989-04-14 1990-04-13 Monoclonal antibody to amyloid peptide

Country Status (1)

Country Link
WO (1) WO1990012870A1 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593846A (en) * 1992-07-10 1997-01-14 Athena Neurosciences Methods for the detection of soluble β-amyloid peptide
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US6245964B1 (en) 1993-10-27 2001-06-12 Elan Pharmaceuticals, Inc. Transgenic rodent comprising APP-Swedish
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6808712B2 (en) 1997-12-02 2004-10-26 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
WO2004098631A1 (en) * 2003-05-08 2004-11-18 Universidad De Zaragoza Alzheimer's disease treatment method
US6875434B1 (en) 1997-12-02 2005-04-05 Neuralab Limited Methods of treatment of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
EP1975179A1 (en) * 2002-09-12 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US7993627B2 (en) 1992-07-10 2011-08-09 Elan Pharmaceuticals, Inc. Methods for determining whether a compound alters the amount of at least one αβ (X-41) peptide and the amount of either total αβ or at least one αβ (X-40) peptide produced by a non-human mammal
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8105594B2 (en) 1998-05-21 2012-01-31 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GLENNER et al., "Alzheimer's disease and Down's Syndrome: sharing of an unique cerebrovascular amyloid fibril protein", BIOCHEM. BIOPHYS. RES. COMM., Vol. 122, No. 3, pages 1131-1135. Published 16 August 1984. *
GLENNER et al., "Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein", BIOCHEM. BIOPHYS. RES. COMM. 120: No. 3, pages 885-890. Published 16 May 1984. *
GODING, "Monoclonal antibodies: Principles and Practice", Published 1983 by ACADEMIC PRESS INC. (London), see pages 56-97 and pages 209-249. *
KANG et al., "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surfacen receptor", NATURE 325: pages 733-736, published 19 February 1989. *
ROBAKIS et al., "Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides", PROC. NATL. ACAD. SCI. 84; pages 4190-4194, Published June 1987. *
SCICUTELLA et al., "Alz-so appears to be able to distinguish between the neuritic plaques of Alzheimer's disease and those of normal aging", SOC. NEUROSE; Abstr. 13:1150, Published 1987, see abstract 316.5. *
SELKOE et al., "Conservation of brain amyloid proteins and humans with Alzheimer's disease", SCIENCE 235: pages 873-877, Published 20 February 1987. *
WOLOZIN et al., "Re-Expression of a developmentally regulated antigen in Alzheimer's Disease and Down's Syndrome", SOC. NEUROSCI; Abstr. 13:1150, Published 1987. See Abstract 316.6. *
WONG et al., "Neuritio plaques and cerebrovascular amyloid in Alzheimer's disease are antigenically related", PROC. NATL. ACAD. SCI. USA 82: pages 8729-8732. Published December 1985. *

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5593846A (en) * 1992-07-10 1997-01-14 Athena Neurosciences Methods for the detection of soluble β-amyloid peptide
US6284221B1 (en) 1992-07-10 2001-09-04 Elan Pharmaceuticals, Inc. Method for identifying β-amyloid peptide production inhibitors
US7993627B2 (en) 1992-07-10 2011-08-09 Elan Pharmaceuticals, Inc. Methods for determining whether a compound alters the amount of at least one αβ (X-41) peptide and the amount of either total αβ or at least one αβ (X-40) peptide produced by a non-human mammal
US7608749B2 (en) 1993-10-27 2009-10-27 Elan Pharmaceuticals, Inc. Monitoring APP cleavage in transgenic rodents comprising an APP Swedish mutation
US6245964B1 (en) 1993-10-27 2001-06-12 Elan Pharmaceuticals, Inc. Transgenic rodent comprising APP-Swedish
US6586656B2 (en) 1993-10-27 2003-07-01 Elan Pharmaceuticals, Inc. Transgenic rodents harboring APP allele having Swedish mutation
US7179953B2 (en) 1993-10-27 2007-02-20 Elan Pharmaceuticals, Inc. Monitoring APP cleavage in transgenic rodents comprising an APP-Swedish mutation
US7811769B2 (en) 1994-11-14 2010-10-12 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7700309B2 (en) 1994-11-14 2010-04-20 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (X->41) and tau
US6787139B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787144B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787138B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6808712B2 (en) 1997-12-02 2004-10-26 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6818218B2 (en) 1997-12-02 2004-11-16 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787140B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6875434B1 (en) 1997-12-02 2005-04-05 Neuralab Limited Methods of treatment of Alzheimer's disease
US6890535B1 (en) 1997-12-02 2005-05-10 Neuralab Limited Pharmaceutical compositions and methods for treatment of amyloid diseases
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6936246B1 (en) 1997-12-02 2005-08-30 Neuralab Limited Passive immunization of ASCR for prion disorders
US6982084B2 (en) 1997-12-02 2006-01-03 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US8642044B2 (en) 1997-12-02 2014-02-04 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US8034339B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US8535673B2 (en) 1997-12-02 2013-09-17 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US6787143B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US9051363B2 (en) 1997-12-02 2015-06-09 Janssen Sciences Ireland Uc Humanized antibodies that recognize beta amyloid peptide
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8105594B2 (en) 1998-05-21 2012-01-31 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
EP1975179A1 (en) * 2002-09-12 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8809010B2 (en) 2003-05-05 2014-08-19 Probiodrug Ag Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases
WO2004098631A1 (en) * 2003-05-08 2004-11-18 Universidad De Zaragoza Alzheimer's disease treatment method
EP2075007A3 (en) * 2003-05-08 2009-11-11 Araclón Biotech, S. L. Treatment for Alzheimer's disease
EP2082747A3 (en) * 2003-05-08 2010-01-13 Araclón Biotech, S. L. Treatment for Alzeimer's disease
EP2305286A3 (en) * 2003-05-08 2011-11-09 Araclon Biotech, S.L. Treatment for Alzeimer's disease
EP2356996A1 (en) * 2003-05-08 2011-08-17 Araclon Biotech, S.L. Treatment for Alzeimer's disease
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase

Similar Documents

Publication Publication Date Title
Ida et al. Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay
Arahata et al. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide
US6238892B1 (en) Monoclonal antibodies directed against the microtubule-associated protein tau
Agnello et al. Evidence for a subset of rheumatoid factors that cross-react with DNA-histone and have a distinct cross-idiotype.
US20070098721A1 (en) Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
Boyd et al. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit.
Wong et al. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related
US7060270B2 (en) Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
US5883227A (en) Multiple sclerosis associated polypeptide
US6376207B1 (en) Assay and reagents for quantifying hBNp
Asami-Odaka et al. Long amyloid. beta.-protein secreted from wild-type human neuroblastoma IMR-32 cells
US4666829A (en) Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5478741A (en) Antibodies to the HRPII protein of plasmodium falciparum
Criado et al. Evidence for unpredicted transmembrane domains in acetylcholine receptor subunits
US6589746B1 (en) Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US7674599B2 (en) Methods of using antibodies to detect alpha-synuclein in fluid samples
Otey et al. Immunolocalization of the gamma isoform of nonmuscle actin in cultured cells.
US6376206B1 (en) Specific antibodies to troponin T, their production and use in a reagent for the determination of myocardial necrosis
US6114133A (en) Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5750349A (en) Antibodies to β-amyloids or their derivatives and use thereof
US5811310A (en) The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US20080025988A1 (en) Monoclonal Antibody And Use Thereof
US20060183154A1 (en) Human ring specific BNP antibodies
US5955317A (en) Antibodies to β-amyloids or their derivatives and use thereof
US5985581A (en) Use of presenilin-1 for diagnosis of alzheimers disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA DK FI HU JP KP KR NO RO SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

NENP Non-entry into the national phase in:

Ref country code: CA